Investigating how cholesterol metabolites signal in the body
Official title: Molecular tools for cholesterol metabolite signaling
Funded at University of Illinois at Chicago · NIH-11015779 · Data updated 2026-11-12
This study is looking at how cholesterol and its byproducts affect our health, especially in relation to diseases like cancer and immune disorders, to find new ways to improve treatments for people dealing with these conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project start | February 1, 2024 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $354,349 |
| NIH project number | 5R35GM152119-02 |
| Project ID | NIH-11015779 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with conditions related to dysregulated cholesterol metabolism, such as cancer or immune disorders.
✕Less likely to help
Patients with conditions unrelated to cholesterol metabolism or those who do not have any metabolic disorders may not benefit from this research.
What this research studies
This research focuses on understanding the role of cholesterol and its metabolites in human health, particularly how they signal within cells and affect diseases like cancer and immune disorders. By developing innovative probes, the research aims to identify how these metabolites interact with proteins and influence various biological processes. Patients may benefit from new therapeutic targets that arise from this understanding, potentially leading to improved treatments for conditions linked to cholesterol metabolism.
Why it matters
Potential benefit: If successful, this research could lead to new therapies targeting cholesterol-related diseases, improving patient outcomes.
How similar studies have gone: Previous research has shown promise in targeting cholesterol metabolites for therapeutic purposes, indicating that this approach could yield significant advancements.
Where this research is happening
-
University of Illinois at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Ondrus, Alison Evelynn — University of Illinois at Chicago
- Study coordinator: Ondrus, Alison Evelynn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.